Evidence map›Paper›PMID 42135281›Full record

ArticleNature communications2026

m

Yucheng Wang, Alice A Daddi, Amir Hosseini, Kazuki Kato, Ehsan Khalili, Håvard T Lindholm, Mengjie Li, Yadong Wang, David C Michael, Catherine A O'Brien and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. mNature communications · 2026
    Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Yucheng Wang *Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford, UK.
Alice A Daddi *Ludwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford, UK.ORCID http://orcid.org/0000-0001-9495-5040
Amir HosseiniLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford, UK.ORCID http://orcid.org/0000-0001-8229-832X
Kazuki KatoMechanistic Immunology Research Unit, Institute of Integrated Research, Institute of Science Tokyo, Bunkyo-ku, Tokyo, Japan.
Ehsan KhaliliLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford, UK.
Håvard T LindholmDepartment of Pathology, Oslo University Hospital-Rikshospitalet, Oslo, Norway.ORCID http://orcid.org/0000-0003-4403-4387
Mengjie LiLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford, UK.
Yadong WangPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
David C MichaelLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford, UK.ORCID http://orcid.org/0009-0000-0675-6202
Catherine A O'BrienPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Daniel D De CarvalhoPrincess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Jan RehwinkelMedical Research Council Translational Immune Discovery Unit, Medical Research Council Weatherall Institute of Molecular Medicine, Radcliffe Department of Medicine, University of Oxford, Oxford, UK.
Parinaz MehdipourLudwig Institute for Cancer Research, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Headington, Oxford, UK. Parinaz.Mehdipour@ludwig.ox.ac.uk.ORCID http://orcid.org/0000-0002-4476-9925

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

How cancer cells evade immune detection despite expressing immunostimulatory retroelement (RE) transcripts remains unclear. In cancer, endogenous REs that escape epigenetic silencing are transcribed and can form double-stranded RNA (dsRNA), which activates innate immune responses through viral mimicry. However, RNA-level mechanisms can limit this effect. Here we show that the m

Indexed as

AdenosineAlu ElementsColorectal NeoplasmsImmunity, InnateMethyltransferasesRNA, Double-StrandedAnimalsCell Line, TumorEpitranscriptomeGene Expression Regulation, NeoplasticHumansMiceRNA MethylationAdenosineMethyltransferasesMETTL3 protein, humanRNA, Double-Stranded

Identifiers

PMID42135281
PMCPMC13377058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.